Cancer Treatment Just Left the Hospital Building

This isn't a one-off. It's a coordinated global regulatory shift.

The Infusion Center Problem

To understand why regulators and health systems are so enthusiastic, you need to understand the math. The global home infusion therapy market hit an estimated $42.4 billion in 2025. The outpatient oncology infusion market sits around $15.1 billion in 2026. These are enormous numbers, and they reflect enormous pressure.

Hospital-based infusion costs between $586 and $798 per day. Home infusion? Roughly $122 to $225 per day. That's a 60–80% cost reduction, depending on the therapy.

For the UK's NHS, which has been actively expanding home-based cancer treatment since COVID forced their hand, the Sarclisa approval slots perfectly into an existing strategy. Subcutaneous nivolumab (a "super-jab" cancer immunotherapy) was approved in the UK in 2025, but it still required a healthcare professional to administer it in clinic. The on-body injector takes the next logical step: the patient does it themselves.

Not Everyone Gets to Go Home (Yet)

Before we declare the infusion center dead, some reality checks.

Wholesale adoption of home-based cancer treatment won't happen overnight. Experts expect initial use will be limited to stable, adherent patients with good support systems and quick access to clinical teams. Multiple myeloma patients often take complex drug cocktails (steroids, proteasome inhibitors, the works), so the at-home piece applies specifically to the Sarclisa injection component.

Hospitals will need new protocols, nurse training on the CirCLIQ device, patient education programs, and robust remote monitoring. Supply chains need to reliably get both the drug and the device into community or home-care settings. None of that is trivial.

But the direction is clear. Think of it as cancer treatment's version of streaming: the content (the drug) is the same, but the delivery model is fundamentally different. And once patients experience the convenience, going back feels impossible.

The Competitive Landscape Is Getting Crowded

Sarclisa isn't alone in the subcutaneous oncology race; it's just the first to pair a cancer drug with a wearable injector. The broader IV-to-SC movement is already well underway:

Darzalex Faspro (daratumumab, also for myeloma) uses a hyaluronidase-boosted subcutaneous injection but requires manual delivery by a healthcare professional. Rybrevant Faspro (amivantamab, for lung cancer) got FDA approval for subcutaneous use in December 2025. Tecentriq Hybreza (atezolizumab, bladder cancer) followed in May 2026.

All of these are manual injections, though. None use an on-body device. That distinction matters because it's the difference between "faster clinic visit" and "you don't need the clinic at all."

For context, on-body injectors have existed in oncology supportive care since 2014, when Amgen's Neulasta Onpro was approved to deliver pegfilgrastim (a white blood cell booster) the day after chemo. But that was a supporting player, not the main act. Sarclisa's CirCLIQ is the first time the actual cancer drug is riding on the device.

What Comes Next

The FDA decision on July 23 will be the big one. If the U.S. greenlights Sarclisa with CirCLIQ, expect a flood of pharma companies pursuing similar reformulations for their antibody portfolios. The regulatory precedent will be set across three major markets (EU, UK, U.S.) within a single quarter.

For patients, the promise is simple: less time in hospitals, more time living. For health systems, it's capacity relief and cost savings. For Sanofi and Enable Injections, it's a first-mover advantage in what could become the default delivery model for a growing number of cancer biologics.

The infusion chair isn't disappearing tomorrow. But it just got its first serious competition.

Exelixis Built a Backup Plan for Its $2B Drug. It Just Hit a Wall.

Exelixis' next-generation drug zanzalintinib missed a key survival endpoint in colorectal cancer, sending shares down 10-12%. With Cabometyx still driving 90% of revenue, the pressure to prove the successor can carry the franchise just got a lot more intense.